AI 'Nano-Rockets': METiS TechBio's Blockbuster IPO Redefines Medicine

HONG KONG – May 13, 2026 – In a stunning display of investor confidence that sent ripples through the global biotechnology sector, METiS TechBio (7666.HK) made a spectacular debut on the Hong Kong Stock Exchange today. Shares of the AI-powered drug delivery firm surged as much as 185% in early trading, cementing its status as a pivotal player in the future of medicine and validating the immense market appetite for a new generation of AI-driven pharmaceutical companies.

The company, which bills itself as the "SpaceX of pharmaceuticals," raised over HKD 2.1 billion (approx. USD 270 million) in what became Hong Kong's largest healthcare IPO of 2026. The offering was met with frenetic demand, with the public tranche oversubscribed by a staggering 6,900 times, locking up over HKD 730 billion in funds. This landmark listing makes METiS TechBio the world's first publicly traded AI-powered drug delivery company, marking a significant milestone not just for the firm but for the entire tech-bio industry.

The 'Nano-Rocket' Engine: A New Era in Drug Delivery

At the heart of the investor excitement is METiS TechBio's proprietary technology platform, NanoForge. This sophisticated system uses artificial intelligence to design and optimize microscopic delivery vehicles—'nano-rockets'—that can transport therapeutic payloads like nucleic acids and proteins directly to diseased cells with unprecedented precision.

This AI-driven approach aims to solve one of the most persistent challenges in medicine: ensuring a drug reaches its target without causing collateral damage to healthy tissue. The company has already demonstrated breakthrough success, achieving targeted delivery to eight key organs and tissues in vivo, including the liver, lungs, central nervous system, and even tumors.

"The future of biomedicine will no longer be simply about 'taking medicine when one falls ill,'" stated Dr. Chris Lai, Co-Founder, Chairman, and CEO of METiS TechBio in a release. "METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells... and reprogram diseased and aging cells into healthy cells."

The NanoForge platform integrates AI foundation models, quantum chemistry simulations, and a vast, proprietary library of over 10 million ionizable lipids. This allows its core solutions—AiTEM for small molecules, AiLNP for lipid nanoparticles, and AiRNA for mRNA sequence design—to dramatically accelerate the drug development process. A prime example is the company's lead candidate, MTS-004, where the AiTEM platform slashed preclinical formulation development time from a typical one to two years down to less than three months.

Investor Frenzy Signals Confidence in AI-Pharma

The overwhelming success of the IPO is a powerful testament to the market's belief in this vision. METiS TechBio's shares, priced at HKD 10.50, opened at HKD 28.68—a 173% premium—and closed the day at HKD 23.80, up 126.67%. This performance was fueled by an exceptional lineup of 18 cornerstone investors who collectively subscribed for USD 148 million.

The diverse group of backers reads like a who's who of global finance and technology. It includes BlackRock, the world's largest asset manager, which led with a USD 50 million investment, alongside global giants like UBS Asset Management and Mirae Asset. The participation of specialized healthcare funds such as Deerfield and RTW, and top-tier tech investors like Hillhouse Capital and IDG Capital, underscores a broad consensus on the company's potential.

Significantly, the IPO also attracted state-level capital, with the Guofengtou Innovation Investment Fund making its first-ever investment in the AI pharmaceutical sector. This, combined with rare joint participation from China's top public fund managers, signals that AI nanodelivery is viewed not just as a promising commercial venture but as a strategic technology critical for future breakthroughs in global biopharmaceuticals.

From Lab to Market: A Pipeline of Precision Medicine

While the technology is futuristic, METiS TechBio is already translating its platform into tangible clinical progress. The company boasts a pipeline of more than 10 products targeting major disease areas like oncology, immunology, and metabolic diseases.

Its most advanced asset, MTS-004, has already completed Phase III clinical trials, making it China's first AI-enabled formulation drug to reach this stage. Designed to treat pseudobulbar affect (PBA), a neurological condition causing uncontrollable laughing or crying, MTS-004 is poised to fill a significant treatment gap in the Chinese market. The company plans to submit a New Drug Application (NDA) later this year.

Further down the pipeline, MTS-105 represents the company's "rocket + satellite" immunotherapy paradigm. This mRNA-based therapy, which has received Orphan Drug Designation from the U.S. FDA, uses a proprietary liver-targeting LNP system to encode a T-cell engager directly within the body to fight liver cancer. Preclinical studies have shown powerful tumor-killing effects and the creation of long-term immune memory, highlighting the potential for in vivo reprogramming of the immune system to combat solid tumors.

This progress is supported by a dual-engine business model that combines internal product development with platform collaborations. With over 30 partnerships with global pharmaceutical companies and research institutions, METiS TechBio has already begun to commercialize its platform, reporting RMB 105 million in revenue for 2025, primarily from upfront payments.

Navigating the Hype: The Long Road to Revolution

Despite the 'SpaceX' moniker and the spectacular IPO, the road to revolutionizing the pharmaceutical industry is long and capital-intensive. The broader AI drug discovery landscape is becoming increasingly competitive, with companies like Insilico Medicine and XtalPi also leveraging AI, though METiS TechBio has carved out a distinct niche by focusing specifically on the critical challenge of drug delivery.

The company's heavy investment in its technology is evident in its financials. From 2023 to 2025, METiS TechBio maintained high R&D expenditures of approximately RMB 270 million, and it continues to operate at a net loss as it scales its operations. The proceeds from the IPO are crucial for fueling this growth. The company plans to allocate approximately 50% of the net proceeds to advance its NanoForge platform and AI infrastructure, with another 20% dedicated to advancing its clinical pipeline. This strategy underscores a long-term commitment to innovation, positioning the company not just for immediate wins but for sustained leadership in the burgeoning field of AI-enabled medicine. The successful launch on the public market provides the fuel, but the journey through the complex inner space of the human body has just begun.